X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (499) 499
Publication (49) 49
Newspaper Article (14) 14
Book Chapter (8) 8
Book / eBook (7) 7
Book Review (6) 6
Patent (5) 5
Web Resource (2) 2
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (287) 287
female (199) 199
male (199) 199
gastroenterology & hepatology (177) 177
middle aged (172) 172
adult (161) 161
index medicus (145) 145
hepatitis c, chronic - drug therapy (115) 115
antiviral agents - therapeutic use (107) 107
drug therapy, combination (84) 84
hepatitis c (84) 84
hepacivirus - genetics (79) 79
interferon-alpha - therapeutic use (76) 76
recombinant proteins (75) 75
aged (74) 74
treatment outcome (71) 71
ribavirin - therapeutic use (69) 69
interferon (65) 65
ribavirin (62) 62
gastroenterology and hepatology (59) 59
genotype (58) 58
cirrhosis (57) 57
polyethylene glycols - therapeutic use (55) 55
plus ribavirin (50) 50
hepatitis (47) 47
hepatitis c virus (44) 44
antiviral agents - adverse effects (42) 42
therapy (42) 42
virus-infection (42) 42
antiviral agents - administration & dosage (41) 41
care and treatment (41) 41
fibrosis (40) 40
rna, viral - blood (39) 39
transplantation (39) 39
hepatitis c, chronic - virology (38) 38
liver - pathology (38) 38
surgery (38) 38
liver (37) 37
adolescent (36) 36
article (36) 36
prospective studies (36) 36
health aspects (34) 34
biopsy (33) 33
drug therapy (33) 33
retrospective studies (33) 33
risk factors (33) 33
alanine transaminase - blood (32) 32
double-blind method (32) 32
ribavirin - administration & dosage (32) 32
chronic hepatitis-c (31) 31
interferon-alpha - administration & dosage (31) 31
hepacivirus - drug effects (30) 30
initial treatment (30) 30
liver diseases (30) 30
liver transplantation (30) 30
medicine, general & internal (30) 30
peginterferon alpha-2a (30) 30
combination therapy (29) 29
infection (29) 29
ribavirin - adverse effects (29) 29
abridged index medicus (28) 28
interferon-alpha - adverse effects (28) 28
clinical trials (27) 27
recurrence (27) 27
viral load (27) 27
natural-history (26) 26
time factors (26) 26
disease progression (25) 25
hepatitis c, chronic - complications (25) 25
young adult (25) 25
patients (24) 24
prevalence (24) 24
united-states (24) 24
drug administration schedule (23) 23
follow-up studies (23) 23
hepacivirus - isolation & purification (23) 23
medicine & public health (23) 23
analysis (22) 22
combination (22) 22
hepatitis c - drug therapy (22) 22
hepatitis c, chronic - pathology (22) 22
hepatology (22) 22
pharmacology & pharmacy (22) 22
dose-response relationship, drug (21) 21
liver cirrhosis (21) 21
liver cirrhosis - virology (21) 21
antiviral agents (20) 20
liver cirrhosis - pathology (20) 20
management (19) 19
polyethylene glycols - administration & dosage (19) 19
recombinant proteins - therapeutic use (19) 19
rna (19) 19
smoking (19) 19
efficacy (18) 18
hepatitis c, chronic - blood (18) 18
peginterferon (18) 18
polyethylene glycols - adverse effects (18) 18
trial (18) 18
genotype & phenotype (17) 17
genotypes (17) 17
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 6, pp. 580 - 593
Journal Article
Gastroenterology, ISSN 0016-5085, 01/2018, Volume 154, Issue 1, pp. 253 - 254
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 2, pp. 583 - 584
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2008, Volume 359, Issue 23, pp. 2442 - 2455
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 27, pp. 2608 - 2617
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 143, Issue 1, pp. 267 - 268
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article